Exklusiver Live-Stream direkt von der World of Trading - 2 Tage mit einzigartigen Themen und Experten. Kostenlos teilnehmen + Videos erhalten. -w-
19.04.2018 23:15:00

Global Chronic Heart Failure Epidemiology and Patient Flow Analysis 2017-2026

DUBLIN, April 19, 2018 /PRNewswire/ --

The "Global Chronic Heart Failure Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.

The research provides insights into Chronic Heart Failure epidemiology, Chronic Heart Failure diagnosed patients, and Chronic Heart Failure treatment rate for US, Japan, and EU5 countries. The research measures key indicators including prevalence of Chronic Heart Failure derived from epidemiological analysis, patients diagnosed with Chronic Heart Failure, and patients treated with a drug therapy.

The research study helps executives estimate Chronic Heart Failure market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The research provides estimates and forecasts of Chronic Heart Failure prevalence, Chronic Heart Failure diagnosis rate, and Chronic Heart Failure treatment rate for the period 2017 - 2026. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan.

Key Topics Covered:

1. Chronic Heart Failure: Disease Definition

2. Global Chronic Heart Failure Patient Flow
2A. Global Chronic Heart Failure Prevalence
2B. Global Chronic Heart Failure Diagnosed Patients
2C. Global Chronic Heart Failure Treated Patients

3. Chronic Heart Failure Patient Flow in the US
3A. Chronic Heart Failure Prevalence in the US
3B. Chronic Heart Failure Diagnosed Patients in the US
3C. Chronic Heart Failure Treated Patients in the US

4. Chronic Heart Failure Patient Flow in Europe
4A. Chronic Heart Failure Prevalence in Europe
4B. Chronic Heart Failure Diagnosed Patients in Europe
4C. Chronic Heart Failure Treated Patients in Europe

5. Chronic Heart Failure Patient Flow in Germany
5A. Chronic Heart Failure Prevalence in Germany
5B. Chronic Heart Failure Diagnosed Patients in Germany
5C. Chronic Heart Failure Treated Patients in Germany

6. Chronic Heart Failure Patient Flow in France
6A. Chronic Heart Failure Prevalence in France
6B. Chronic Heart Failure Diagnosed Patients in France
6C. Chronic Heart Failure Treated Patients in France

7. Chronic Heart Failure Patient Flow in Spain
7A. Chronic Heart Failure Prevalence in Spain
7B. Chronic Heart Failure Diagnosed Patients in Spain
7C. Chronic Heart Failure Treated Patients in Spain

8. Chronic Heart Failure Patient Flow in Italy
8A. Chronic Heart Failure Prevalence in Italy
8B. Chronic Heart Failure Diagnosed Patients in Italy
8C. Chronic Heart Failure Treated Patients in Italy

9. Chronic Heart Failure Patient Flow in UK
9A. Chronic Heart Failure Prevalence in UK
9B. Chronic Heart Failure Diagnosed Patients in UK
9C. Chronic Heart Failure Treated Patients in UK

10. Chronic Heart Failure Patient Flow in Japan
10A. Chronic Heart Failure Prevalence in Japan
10B. Chronic Heart Failure Diagnosed Patients in Japan
10C. Chronic Heart Failure Treated Patients in Japan

For more information about this report visit https://www.researchandmarkets.com/research/qzn33g/global_chronic?w=5


Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


 

Cision View original content:http://www.prnewswire.com/news-releases/global-chronic-heart-failure-epidemiology-and-patient-flow-analysis-2017-2026-300633179.html

SOURCE Research and Markets

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!